Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology

Prognosis, Risk Scores, and Long-Term Outlook

At a Glance

In myeloproliferative neoplasms (MPNs), a risk score predicts the likelihood of future events like blood clots or disease progression. Doctors use your age, blood counts, and genetic mutations to calculate this score, which guides whether you need simple monitoring or more proactive treatment.

Understanding your long-term outlook with a myeloproliferative neoplasm (MPN) involves looking at “risk scores.” In the world of chronic blood cancers, risk doesn’t mean you are in immediate danger; rather, it is a tool doctors use to predict the likelihood of future events, such as blood clots or the disease changing into a more aggressive form [1][2].

How Risk is Measured

Different MPN subtypes use different scoring “calculators.” These models combine your age, your blood counts, and your genetic profile to give a clearer picture of your journey.

Essential Thrombocythemia (ET)

The IPSET-thrombosis score is the most common tool for ET. It focuses primarily on your risk of developing a blood clot [3].

  • Key factors: Age (over 60), history of prior blood clots, and whether you have the JAK2 mutation [2][4].

Myelofibrosis (PMF)

For myelofibrosis, scores like DIPSS (Dynamic International Prognostic Scoring System) and MIPSS70 (Mutation-Enhanced International Prognostic System) are used to estimate survival and the need for intensive treatments like a bone marrow transplant [5][6].

  • DIPSS: Uses clinical factors like age, hemoglobin levels, white blood cell counts, and symptoms (night sweats, fevers) [6].
  • MIPSS70: Adds a layer of genetic “detective work” by looking for specific mutations [5].

High-Molecular-Risk (HMR) Mutations

While the “driver mutations” (JAK2, CALR, MPL) tell us you have an MPN, a second group of mutations—called High-Molecular-Risk (HMR) mutations—can act like a “speed boost” for the disease [1]. These include:

  • ASXL1, SRSF2, EZH2, IDH1/2: If these are found in your marrow, it may mean the disease has a higher chance of progressing or a shorter timeline for survival [7][8][9].
  • Knowing your HMR status helps your doctor decide if you should stay on a “gentle” treatment or if you need to be evaluated for a curative bone marrow transplant [10][11].

The Timeline of Progression

It is common to worry about your disease “turning into” something else. This process is called progression or transformation.

  • To Myelofibrosis: Patients with PV or ET can eventually develop “secondary” myelofibrosis (post-PV MF or post-ET MF) [12]. This usually happens slowly, over a decade or more [13].
  • To Leukemia: A small percentage of MPN cases may transform into Acute Myeloid Leukemia (AML) [14]. While rare, the risk increases the longer you have the disease or if you have specific HMR mutations [9][13].

Interpretation Guide: What “High Risk” Really Means

Risk Level What it usually means for your care
Low Risk Focus is on monitoring and preventing blood clots. You may only need aspirin or phlebotomy [15].
Intermediate Risk Your doctor may add a “count-lowering” medication (like Hydroxyurea or Interferon) to reduce the burden on your body [15].
High Risk This is a signal to be more proactive. It may involve clinical trials, newer JAK inhibitors, or discussing a transplant [10][11].

Remember, these models are based on large groups of people. They are a “map,” but they are not your specific “destiny.” Every patient’s biology is slightly different, and new treatments are constantly shifting these statistics in a more positive direction [3][1].

Back to Home Page

Common questions in this guide

What does high risk mean for my MPN?
A high-risk MPN means there is a greater chance of blood clots or the disease progressing faster. It signals to your doctor that you may need more proactive treatments, such as newer medications, clinical trials, or a bone marrow transplant evaluation.
What are High-Molecular-Risk (HMR) mutations?
HMR mutations, such as ASXL1 or EZH2, are specific genetic changes in your bone marrow that can act like a speed boost for the disease. If you have these mutations, your MPN may have a higher chance of progressing, which helps your doctor tailor your treatment plan.
Can an MPN turn into leukemia?
A small percentage of MPNs can transform into Acute Myeloid Leukemia (AML) over time. This rare risk generally increases the longer you have had the disease or if you have certain high-molecular-risk genetic mutations.
What is the DIPSS score for myelofibrosis?
The DIPSS is a risk calculator used for myelofibrosis that estimates your long-term outlook. It looks at clinical factors like your age, hemoglobin levels, white blood cell counts, and symptoms like night sweats to help guide your treatment needs.
How is my risk of blood clots measured if I have Essential Thrombocythemia?
For Essential Thrombocythemia (ET), doctors often use the IPSET-thrombosis score to measure your risk of developing a blood clot. This score focuses on your age, whether you have had a blood clot before, and if you have the JAK2 genetic mutation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific risk score (e.g., DIPSS, IPSET, or MIPSS70), and what category does that put me in (Low, Intermediate, or High)?
  2. 2.Did my testing look for 'High-Molecular-Risk' (HMR) mutations like ASXL1, SRSF2, or EZH2, and how do those impact my outlook?
  3. 3.Based on my current risk score, should we be considering more aggressive treatments like a bone marrow transplant, or is 'watch and wait' still appropriate?
  4. 4.How often should we repeat my molecular testing or bone marrow biopsy to monitor for signs of progression?
  5. 5.What is my specific risk of my disease turning into myelofibrosis or leukemia over the next 10 years?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Molecular profiling in MPN: who should have it and why?

    Chee A, Mead AJ

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):524-534 doi:10.1182/hematology.2024000576.

    PMID: 39644028
  2. 2

    Update from the latest WHO classification of MPNs: a user's manual.

    Passamonti F, Maffioli M

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):534-542 doi:10.1182/asheducation-2016.1.534.

    PMID: 27913526
  3. 3

    Prognostic models in the myeloproliferative neoplasms.

    Grinfeld J

    Blood reviews 2020; (42()):100713 doi:10.1016/j.blre.2020.100713.

    PMID: 32532453
  4. 4

    Genetic Risk Assessment in Myeloproliferative Neoplasms.

    Tefferi A, Vannucchi AM

    Mayo Clinic proceedings 2017; (92(8)):1283-1290 doi:10.1016/j.mayocp.2017.06.002.

    PMID: 28778261
  5. 5

    A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic.

    How J, Hobbs GS

    Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(9)):1271-1278.

    PMID: 32886896
  6. 6

    Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.

    Tefferi A, Guglielmelli P, Lasho TL, et al.

    British journal of haematology 2020; (189(2)):291-302 doi:10.1111/bjh.16380.

    PMID: 31945802
  7. 7

    Pathogenesis and management of high molecular risk myeloproliferative neoplasms.

    Ling VY, Heidel FH, Bywater MJ

    Haematologica 2025; (110(4)):863-876 doi:10.3324/haematol.2023.283987.

    PMID: 39633552
  8. 8

    [Efficacy of ruxolitinib and prognostic factors in patients with myelofibrosis stratified by age].

    Liu XH, Yu Y, Yan FM, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2025; (46(8)):722-730 doi:10.3760/cma.j.cn121090-20250113-00025.

    PMID: 41087180
  9. 9

    Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model.

    Vallapureddy RR, Mudireddy M, Penna D, et al.

    Blood cancer journal 2019; (9(2)):12 doi:10.1038/s41408-019-0175-y.

    PMID: 30683837
  10. 10

    Accelerated and Blast Phase Myeloproliferative Neoplasms.

    Jain T, Rampal RK

    Hematology/oncology clinics of North America 2021; (35(2)):325-335 doi:10.1016/j.hoc.2020.12.008.

    PMID: 33641872
  11. 11

    Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

    Zeeh FC, Meyer SC

    Hamostaseologie 2021; (41(3)):197-205 doi:10.1055/a-1447-6667.

    PMID: 34192778
  12. 12

    Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.

    Verma T, Papadantonakis N, Peker Barclift D, Zhang L

    Cancers 2024; (16(3)) doi:10.3390/cancers16030514.

    PMID: 38339265
  13. 13

    Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study.

    Batyrbekova N, Landtblom AR, Hultcrantz M, et al.

    European journal of haematology 2026; (116(6)):850-862 doi:10.1111/ejh.70141.

    PMID: 41717866
  14. 14

    Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.

    Bartels S, Vogtmann J, Schipper E, et al.

    European journal of haematology 2021; (106(4)):520-528 doi:10.1111/ejh.13579.

    PMID: 33460496
  15. 15

    Contemporary approach to essential thrombocythemia and polycythemia vera.

    Aruch D, Mascarenhas J

    Current opinion in hematology 2016; (23(2)):150-60 doi:10.1097/MOH.0000000000000216.

    PMID: 26717193

This page explains MPN prognosis and risk scoring models for educational purposes. Always discuss your specific risk score, genetic mutations, and overall outlook with your hematologist or oncologist.

Get notified when new evidence is published on Myeloproliferative neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.